Posterior Reversible Encephalopathy Syndrome (PRES) as an Initial Presentation of Systemic Lupus Erythematosus (SLE)

Babu Philip¹, Sandhya Limaye¹, Thanakrishnan G² and Arun Aggarwal³*

¹Department of Immunology, Concord Hospital, Concord NSW 2039, Australia
²Department of Intensive Care, Concord Hospital, Concord NSW 2039, Australia
³Department of Neurology, Concord Hospital, Concord NSW 2039, Australia

Abstract

Background: Posterior Reversible Encephalopathy Syndrome (PRES) refers to a clinico-radiological syndrome characterized by headache, altered mental function, visual disturbance, seizures and transient posterior changes on neuro-imaging.

Case report: We present a case of a 38 year old female who presented with sudden onset behavioural change, visual disturbance and subsequent witnessed generalized tonic-clonic seizure. A cerebral MRI showed extensive signal abnormality consistent with vasogenic oedema in the cerebellar hemispheres and subcortical white matter of the occipito-parietal lobes consistent with a neuro-radiological diagnosis of Posterior Reversible Encephalopathy Syndrome (PRES).

Conclusion: We describe a case of a dramatic first presentation of Systemic Lupus Erythematosus (SLE) with neurological manifestations of PRES, occurring in the absence of accompanying evidence of lupus nephritis, cerebritis or other usual causative factors, such as immunosuppression.

Keywords: Posterior reversible encephalopathy syndrome; Systemic lupus; Erythematosus

Introduction

Posterior Reversible Encephalopathy Syndrome (PRES), first described in 1996, is a neuro-radiological entity characterized by headache, altered mental function, visual disturbance, seizures and posterior transient changes on neuro-imaging [1]. Classical MRI findings were initially described as bilateral sub-cortical hyper-intense areas involving occipital and parietal lobes although involvement of other lobes including the cerebellum have since been reported [2,3].

Systemic Lupus Erythematosus (SLE) is a chronic multisystem inflammatory disease that follows a relapsing and remitting course. It is characterized by an auto-antibody response to nuclear and cytoplasmic antigens. SLE can affect any organ system, but mainly involves the skin, joints, kidneys, blood cells, and nervous system [4].

PRES can occur at anytime in an SLE patient, but the usual identified risk factors are hypertension, renal involvement and the use of immunosuppressive agents, particularly cyclosporine [4].

Case Presentation

A 38 year old female, Fijian Indian descent, presented with sudden onset behavioural change, confusion, visual disturbance and subsequent witnessed generalized tonic-clonic seizure on a background of a 1 week history of a probable viral prodrome of vomiting and diarrhoea. There were no other neurological symptoms at the time. On arrival to the emergency department, she was noted to be hypertensive with a BP of 176/104 mmHg. This was treated acutely with intravenous hydralazine, emergency department, she was noted to be hypertensive with a BP of

Received April 09, 2012; Accepted May 05, 2012; Published May 18, 2012


Copyright: © 2012 Philip B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Corresponding author: Arun Aggarwal, Associate Professor, Department of Neurology, Concord Hospital, Concord NSW 2039, Australia, E-mail: arun.a@sydney.edu.au
of 1:640, markedly elevated dsDNA antibody level of > 80 KIU/L, elevated C-reactive protein of 181 and low C3 and C4. A diagnosis of Systemic Lupus Erythematosus was made and intravenous high-dose methyl prednisone, 1 gram daily, was instituted with clinical and blood pressure improvement.

Subsequent directed history from family revealed a 2 year history of recurrent skin rash over the lower limbs, mild alopecia and anaemia. There was no history of arthritis, malar rash, miscarriage or thromboembolism. She also had no previous history of hypertension.

The patient’s condition improved gradually, with an improvement in mental state, cognition and there were no further seizures. Eight days later, she was extubated and the extra-ventricular drain removed. Anti-cardiolipin and beta-2-glycoprotein 1 antibodies were not detected although lupus anti-coagulant was positive. Even though she had a normal urea and creatinine, a renal biopsy was performed due to the presence of proteinuria (0.5g/day) and persisting microscopic haematuria. This revealed changes consistent with hypertension and a resolving post-infective or focal proliferative glomerulonephritis, rather than lupus nephritis.

Prior to discharge, she was commenced on Mycophenolate, 500 mg twice a day, and a weaning regimen of oral prednisone. Long-term, the patient has shown a response with no further neurological symptoms, and improvement in dsDNA antibody, C3 and C4 to near-normal levels. A repeat MRI at 3 months showed a marked improvement with near-complete resolution of the abnormal high T2 signal in cerebral and cerebellar hemispheres (Figure 2).

**Discussion**

Posterior Reversible Encephalopathy Syndrome (PRES) is a neuro-radiological entity characterized by headache, altered mental function, visual disturbance, seizures and posterior transient changes on neuro-imaging [1]. Classical MRI findings were initially described as bilateral sub-cortical hyper-intense areas involving occipital and parietal lobes although involvement of other lobes including the cerebellum have since been reported [2,3].

PRES has been described in association with systemic vasculitis, thrombotic thrombocytopenic purpura, haemolytic uraemic syndrome, infection and other miscellaneous conditions [7]. PRES has also been described in association with a number of immunosuppressive and cytotoxic agents including corticosteroids, cyclophosphamide, mycophenolate and rituximab [7]. Although typically a reversible entity, some patients have developed permanent neurological deficits after an episode of PRES [7].

Although the exact pathogenesis of PRES remains unclear, vasogenic brain oedema secondary to hypertensive encephalopathy and disordered cerebral autoregulation play a major role. The posterior circulation, supplied by the vertebro-basilar system has poor sympathetic innervations and is therefore frequently affected. Vascular endothelial toxicity and endothelial dysfunction due to immunosuppression or inflammatory disease activity has also been proposed [1] and is supported by the description of PRES in normotensive patients [5].

Systemic lupus erythematosus (SLE) is a chronic multisystem inflammatory disease that follows a relapsing and remitting course. It is characterized by an auto-antibody response to nuclear and cytoplasmic antigens. SLE can affect any organ system, but mainly involves the skin, joints, kidneys, blood cells, and nervous system [4]. PRES can occur at anytime in an SLE patient, but the usual identified risk factors are hypertension, renal involvement and the use of immunosuppressive agents, particularly cyclosporine [5]. The mainstay of treatment is supportive control of BP and seizures, withdrawal of an offending drug and directed treatment of systemic SLE activity including corticosteroids and cyclophosphamide. The challenge of treatment thus is balancing the requirement for immunosuppression for management of disease activity against the risk of immunosuppression-associated disease or relapse.

This case demonstrates a very dramatic first presentation of SLE with neurological manifestations of PRES, rather than hypertensive encephalopathy with lupus cerebritis [8,9] occurring in the absence of accompanying lupus nephritis or other causative factors. In a case series by Leroux et al. [10] 91% of patients with SLE and PRES had associated lupus nephritis. Other published case series of PRES in SLE are consistent with the majority of patients having accompanying nephritis [5,8]. In a recent case series by Varaprasad et al. [11] PRES occurred as early as 1.5 months of initial diagnosis of SLE being made. Even in Baizabal-Carvallo et al. [12] review paper on PRES due to acute lupus activity, all 21 cases had known SLE at the time of presentation with PRES.
Conclusion

To our knowledge, this is the first reported case of PRES leading to a diagnosis of SLE. Given that our patient was treatment-naïve, this highlights the ability of active SLE to cause PRES in its own right, without the confounding causative role of immunosuppression and renal impairment.

References